Explore 3 Stock Ideas & Industry Insights Download Free Report

Premium

US Sector Momentum Analysis: Industrials Break Out as Energy Collapses

The US sector rotation on April 1, 2026, showcased a dramatic structural shift. As the momentum chart illustrates, the market is aggressively unwinding its concentrated Energy positioning and redistributing that capital back into cyclical growth and technology. The synchronized leftward drift seen in previous …

Robert Luong | 01 April 2026

S&P 500: A Dead Cat Bounce in Bulls' Clothing

S&P 500 Daily Price Chart. Source: tradingview.com, Analysis by Kalkine Group

Nitish Kishor | 01 April 2026

SanDisk Corp. Technical Analysis: Rebound from Trendline Support Amid Ongoing Consolidation

Trendline Support: Early Signs of StabilitySanDisk Corp. has recently shown signs of resilience after finding support at a well-defined rising trendline. This technical level has acted as a cushion for the stock, preventing further downside and allowing prices to drift higher in the near …

Nitish Kishor | 01 April 2026

Micron Finds Fleeting Footing, But the Bears Have Not Left the Building

Micron Technology shares have staged a modest rebound after finding support at a falling trendline, offering bulls a moment of relief in what has otherwise been a bruising stretch for the memory chipmaker. But technical analysts caution against reading too much into the recovery …

Nitish Kishor | 01 April 2026

Biotech Briefing: Cyclerion (NASDAQ: CYCN) Merges Into Alzheimer's Play, ORIC (NASDAQ: ORIC) Falls on Phase 1b Data Despite Promising Results

Cyclerion Therapeutics (NASDAQ: CYCN)is effectively ceding its identity in a definitive all-stock merger with privately held Korsana Biosciences, with the combined entity set to trade on Nasdaq under the new tickerKRSA. The transaction arrives backed by an oversubscribed $380 million private financing round led …

Nitish Kishor | 01 April 2026

Biotech Briefing: Cyclerion (NASDAQ: CYCN) Merges Into Alzheimer's Play, ORIC (NASDAQ: ORIC) Falls on Phase 1b Data Despite Promising Results

Cyclerion Therapeutics (NASDAQ: CYCN)is effectively ceding its identity in a definitive all-stock merger with privately held Korsana Biosciences, with the combined entity set to trade on Nasdaq under the new tickerKRSA. The transaction arrives backed by an oversubscribed $380 million private financing round led …

Nitish Kishor | 01 April 2026

IO Biotech Files for Chapter 7 and Sheds 29% as Cancer Vaccine Programme Fails to Find Footing

IO Biotech (NASDAQ: IOBT) filed for Chapter 7 bankruptcy in the US Bankruptcy Court for the District of Delaware on March 31st, marking one of the more complete corporate collapses in the immuno-oncology space this year. The company simultaneously ceased all operations, terminated its …

Nitish Kishor | 01 April 2026